Macrolide antibiotics in paediatric infectious diseases

Drugs

Volumn 51, Issue 4, 1996, Pages 515-536

  Guay, David R P ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b REGIONS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; CYCLOSPORIN; DIGOXIN; ERYTHROMYCIN; MACROLIDE; ROXITHROMYCIN; THEOPHYLLINE;

ABDOMINAL CRAMP; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; CHILD; CHOLESTATIC HEPATITIS; DIARRHEA; DRUG CHOICE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; LIVER DYSFUNCTION; LYMPHATIC SYSTEM DISEASE; MALAISE; MENTAL DISEASE; METABOLIC DISORDER; NAUSEA; NUTRITIONAL DISORDER; ORAL DRUG ADMINISTRATION; OTOTOXICITY; PEDIATRICS; RESPIRATORY TRACT INFECTION; REVIEW; SKIN INFECTION; TASTE DISORDER; THROMBOPHLEBITIS; VERTIGO; VOMITING; WHEEZING;

CAMPYLOBACTER; CHLAMYDIA; HAEMOPHILUS INFLUENZAE; HELICOBACTER PYLORI; LEGIONELLA; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM AVIUM COMPLEX; MYCOPLASMA;

EID: 0029870638     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651040-00002     Document Type: Review

References (205)

1. Malmborg A-S. The renaissance of erythromycin. J Antimicrob Chemother 1986; 18: 293-6
2. Kirst HA. New macrolides: expanded horizons for an old class of antibiotics. J Antimicrob Chemother 1991; 28: 787-90
3. Kirst HA, Sides GD. New directions for macrolide antibiotics: structural modifications and in vitro activity. Antimicrob Agents Chemother 1989; 33: 1413-8
4. Mazzei T, Mini E, Novelli A, et al. Chemistry and mode of action of macrolides. J Antimicrob Chemother 1993; 31 Suppl. C: 1-9
5. Brittain DC. Erythromycin. Med Clin North Am 1987; 71: 1147-54
6. Graham EM. Erythromycin. Obstet Gynecol Clin North Am 1992; 19: 539-49
7. Smilack JD, Wilson WR, Cockerill III FR. Tetracyclines, chloramphenicol, erythromycin, clindamycin, and metronidazole. Mayo Clin Proc 1991; 66: 1270-80
8. Brisson-Noel A, Trieu-Cuot P, Courvalin P. Mechanism of action of spiramycin and other macrolides. J Antimicrob Chemother 1988; 22 Suppl. B: 13-23
9. Segreti J, Trenholme GM. Antibiotics I: beta-lactam antibiotics, the tetracyclines, chloramphenicol, erythromycin, clindamycin, metronidazole, and the quinolones. Clin Chest Med 1986; 7: 393-412
10. Washington JA II, Wilson WR. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (first of two parts). Mayo Clin Proc 1985; 60: 189-203
11. Tejedor F, Ballesta JPG. Components of the macrolide binding site on the ribosome. J Antimicrob Chemother 1985; 16 Suppl. A: 53-62
12. Piscitelli SC, Danziger LH, Rodvold KA. Clarithromycin and azithromycin: new macrolide antibiotics. Clin Pharm 1992; 11: 137-52
13. Whitman MS, Tunkel AR. Azithromycin and clarithromycin: overview and comparison with erythromycin. Infect Control Hosp Epidemiol 1992; 12: 357-68
14. Ballow CH, Amsden GW. Azithromycin: the first azalide antibiotic. Ann Pharmacother 1992; 26: 1253-61
15. Sturgill MG, Rapp RP, Clarithromycin: review of a new macrol de antibiotic with improved microbiologic spectrum and favorable pharmacokinetic and adverse event profiles. Ann Pharmacother 1992; 26: 1099-108
16. Bahal N, Nahata MC. The new macrolide antibiotics: azithromycin, clarithromycin, dirithromycin, and roxithromycin. Ann Pharmacother 1992; 26: 46-55
17. Drew RH, Gallis HA. Azithromycin - spectrum of activity, pharmacokinetics, and clinical applications. Pharmacotherapy 1992; 12: 161-73
18. Menninger JR. Functional consequences of binding macrolides to ribosomes. J Antimicrob Chemother 1985; 16 Suppl. A: 23-34
19. Shen Jurnikar N. Erythromycin. Ind Pediatr 1988; 25: 780-3
20. Stein GE, Havlichek DH. The new macrolide antibiotics. Postgrad Med 1992; 92 (1): 269-72, 277-80, 282
21. Hammerschlag MR. Azithromycin and clarithromycin. Pediatr Am 1993; 22: 161-6
22. Williams JD, Sefton AM. Comparison of macrolide antibiotics. J Antimicrob Chemother 1993; 31 Suppl. C: 11-26
23. Young RA, Gonzalez JP, Sorkin EM. Roxithromycin: a review of ts antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1989; 37: 8-41
24. Bebeur C, Dupon M, Renaudin H, et al. Potential improvements in therapeutic options for mycoplasmal respiratory infections. Clin Infect Dis 1993; 17 Suppl. 1: S202-7
25. Hejzlar M, Novotny F, Stastna L, et al. Roxithromycin - a new macrolide derivative. J Hyg Epidemiol Microbiol Immunol 1989; 33: 487-93
26. Peter DH, Friedel HA, McTavish D. Azithromycin: a review of its antimicrobial activity, pharmacokinetic properties, and clinical efficacy. Drugs 1992 Nov; 44 (5): 750-99
27. Ball P. The future role and importance of macrolides. J Hosp Infect 1991; 19 Suppl. A: 47-59
28. Markham A, Faulds D. Roxithromycin: an update of its antimicrobial activity, pharmacokinetic properties and therapeutic use Drugs 1994 Aug; 48 (2): 297-326
29. ®). Conn Med 1992; 56: 371-4
30. Peter DH, Clissold SP. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992 Jul; 44 (1): 117-64
31. Kanatani MS, Guglielmo BJ. The new macrolides: azithromyicin and clarithromycin. West J Med 1994; 160: 31-7
32. Goldman MP, Longworth DL. The role of azithromycin and clarithromycin in clinical practice. Cleve Clin J Med 1993; 60: 359-64
33. Roblin PM, Montalban G, Hammerschlag MR. Susceptibilities to clarithromycin and erythromycin of isolates of Chlamydia pneumoniae from children with pneumonia. Antimicrob Agents Chemother 1994; 38: 1588-9
34. Stott GA. New macrolide antibiotics: clarithromycin and azithromycin. Am Fam Phys 1992; 46: 863-9
35. Hardy DJ, Guay DRP, Jones RN. Clarithromycin, a unique macrolide: a pharmacokinetic, microbiological, and clinical overview. Diagn Microbiol Infect Dis 1992; 15: 39-53
36. Courvalin P, Ounissi H, Arthur M. Multiplicity of macrolide-lincosamide-streptogramin antibiotic resistance determinants. J Antimicrob Chemother 1985; 16 Suppl. A: 91-100
37. Neu HC. Current mechanisms of resistance to antimicrobial agents in microorganisms causing infection in the patient at risk for infection. Am J Med 1984; 76 (5A): 11-27
38. O'Brien TF, Task Force 2. Resistance of bacteria to antibacterial agents: report of task force 2. Rev Infect Dis 1987; 9 Suppl. 3: S244-60
39. Horaud T, Le Bouguenec C, Pepper K. Molecular genetics of resistance to macrolides, lincosamides and streptogramin B (MLS) in streptococci. J Antimicrob Chemother 1985; 16 Suppl. A: 111-35
40. Novick RP, Murphy E. MLS-resistance determinants in Staphylococcus aureus and their molecular evolution. J Antimicrob Chemother 1985; 16 Suppl. A: 101-10
41. Weisblum B. Inducible resistance to macrolides, lincosamides and streptogramin type B antibiotics: the resistance phenotype, its biological diversity, and structural elements that regulate expression - a review. J Antimicrob Chemother 1985; 16 Suppl. A: 63-90
42. Duval J. Evolution and epidemiology of MLS resistance. J Antimicrob Chemother 1985; 16 Suppl. A: 137-49
43. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3: 171-96
44. Thabaut A, Meyran M, Huerre M. Evolution and present situation of Staphylococcus aureus sensitivity to MLS in hospital (1975-83). J Antimicrob Chemother 1985; 16 Suppl. A: 205-7
45. Bass JW, Weisse ME, Plymyer MR, et al. Decline of erythromycin resistance of group A β-hemolytic streptococci in Japan. Arch Pediatr Adolesc Med 1994; 148: 67-71
46. Lonks JR, Medeiros AA. High rate of erythromycin and clarithromycin resistance among Streptococcus pneumoniae isolates from blood cultures from Providence, RI. Antimicrob Agents Chemother 1993; 37: 1742-5
47. Welby PL, Keller DS, Cromien JL, et al. Resistance to penicillin and non-beta-lactam antibiotics of Streptococcus pneumoniae at a children's hospital. Pediatr Infect Dis J 1994; 13: 281-7
48. Coonan KM, Kaplan EL. In vitro susceptibility of recent North American group A streptococcal isolates to eleven oral antibiotics. Pediatr Infect Dis J 1994; 13: 630-5
49. Periti P, Mazzei T, Mini E, et al. Clinical pharmacokinetic properties of the macrolide antibiotics (part I ). Clin Pharmacokinet 1989; 16: 193-214
50. Periti P, Mazzei T, Novelli A, et al. Clinical pharmacokinetic properties of the macrolide antibiotics (part II). Clin Pharmacokinet 1989; 16: 261-82
51. Griffith RS. Pharmacology of erythromycin in adults. Pediatr Infect Dis J 1986; 5: 130-40
52. Bergogne-Berezin E. Tissue distribution of roxithromycin. J Antimicrob Chemother 1987; 20 Suppl. B: 113-20
53. van den Broek PJ. Antimicrobial drugs, microorganisms, and phagocytes. Rev Infect Dis 1989; 11: 213-45
54. Hand WL, King-Thompson NL. The entry of antibiotics into human monocytes. J Antimicrob Chemother 1989; 23: 681-9
55. Ishiguro M, Kogu H, Kohno S, et al. Penetration of macrolides into human polymorphonuclear leucocytes. J Antimicrob Chemother 1989; 24: 719-29
56. Westphal J-F, Brogard J-M. Clinical pharmacokinetics of new antibacterial agents in liver disease. Clin Pharmacokinet 1993; 24: 46-58
57. Osono T, Umezawa H. Pharmacokinetics of macrolides, lincosamines and streptogramins. J Antimicrob Chemother 1985; 16 Suppl. A: 151-66
58. Nilsen OG. Comparative pharmacokinetics of macrolides. J Antimicrob Chemother 1987; 20 Suppl. B: 81-8
59. Puri SK, Lassman HB. Roxithromycin: a pharmacokinetic review of a macrolide. J Antimicrob Chemother 1987; 20 Suppl. B: 89-100
60. Lassman HB, Puri SK, Ho I, et al. Pharmacokinetics of roxithromycin (RU965). J Clin Pharmacol 1988; 28: 141-52
61. DeRose V, Ferrara A, Mangiarotti P, et al. Penetration of roxithromycin in bronchial secretions. Int J Clin Pharm Res 1988; 8: 107-10
62. Harvengt C. Drugs recently released in Belgium: octreotide-roxithromycin. Acta Clin Belg 1989; 44: 205-8
63. Kropec A, Schmidt-Eisenlohr E, Daschner FD. Concentrations of roxithromycin (RU 28965) in serum and in sinus mucosa [letter]. Infection 1988; 16: 250
64. Kirst HA, Sides GD. New directions for macrolide antibiotics: pharmacokinetics and clinical efficacy. Antimicrob Agents Chemother 1989; 33: 1419-22
65. Rodvold KA, Piscitelli SC. New oral macrolide and fluoroquinolone antibiotics: an overview of pharmacokinetics, interactions, and safety. Clin Infect Dis 1993; 17 Suppl. 1: S192-9
66. Fraschini F, Scaglione F, Demartini G. Clarithromycin clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 189-204
67. Klein JO. Clarithromycin: where do we go from here? Pediatr Infect Dis J 1993; 12: S148-51
68. Lode H. The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis 1991; 10: 807-12
69. Wise R. Macrolide progress. J Antimicrob Chemother 1990; 26: 5-6
70. Mazzei T, Surrenti C, Novelli A, et al. Pharmacokinetics of azithromycin in patients with impaired hepatic function. J Antimicrob Chemother 1993; 31 Suppl. E: 57-63
71. Nahata MC, Koranyi KI, Gadgil SD, et al. Pharmacokinetics of azithromycin in pediatric patients after oral administration of multiple doses of suspension. Antimicrob Agents Chemother 1993; 37: 314-6
72. Nahata MC, Koranyi KI, Luke DR, et al. Pharmacokinetics of azithromycin in pediatric patients with acute otitis media. Antimicrob Agents Chemother 1995; 39: 1875-7
73. Gan VN, Chu S-Y, Kusmiesz HT, et al. Pharmacokinetics of a clarithromycin suspension in infants and children. Antimicrob Agents Chemother 1992; 36: 2478-80
74. Husson RN, Ross LA, Sandelli S, et al. Orally administered clarithromycin for the treatment of systemic Mycobacterium avium complex infection in children with acquired immunodeficiency syndrome. J Pediatr 1994; 124: 807-14
75. Kafetzis DA, Krotsi-Laskari M, Tremblay D, et al. Multiple dose pharmacokinetics in infants and children treated with roxithromycin. Br J Clin Prac 1988; Suppl. 55: 58
76. Demotes-Mainard FM, Vincon GA, Albin HC. Pharmacokinetics of a new macrolide, roxithromycin, in infants and children. J Clin Pharmacol 1989; 29: 752-6
77. Guay DRP, Craft JC. Overview of the pharmacology of clarithromycin suspension in children and a comparison with that in adults. Pediatr Infect Dis J 1993; 12: S106-11
78. Butler Dr, Kuhn RJ, Chandler MHH. Pharmacokinetics of antiinfective agents in paediatric patients. Clin Pharmacokinet 1994; 26: 374-95
79. Papp CM, Nahata MC. Clinical pharmacokinetics of antibacterial drugs in neonates. Clin Pharmacokinet 1990; 19: 280-318
80. Hayakawa F, Kuno K, Nakao Y, et al. Laboratory and clinical studies on clarithromycin in the field of pediatrics. Jpn J Antibiot 1989; 42: 324-38
81. Ito S, Mayumi M, Mikawa H. Clinical evaluation of clarithromycin in pediatric patients. Jpn J Antibiot 1989; 42: 343-51
82. Iwai N, Taneda Y, Miyazu M, et al. Basic and clinical studies on clarithromycin in pediatrics. Jpn J Antibiot 1989; 42: 304-22
83. Akita H, Sato Y, Iwata S, et al. Laboratory and clinical studies on clarithromycin in pediatrics. Jpn J Antibiot 1989; 42: 264-80
84. Nishimura T, Tabuki K, Aoki S, et al. Laboratory and clinical studies of clarithromycin in pediatric fields. Jpn J Antibiot 1989; 42: 353-69
85. Yanagishima M, Yanai M, Yanagi T, et al. Pharmacokinetic and clinical studies of clarithromycin in the pediatric field. Jpn J Antibiot 1989; 42: 495-511
86. Motohiro T, Yoshinaga Y, Sasaki H, et al. Pharmacokinetics of clarithromycin granules and tablets in children. Jpn J Antibiot 1989; 42: 465-94
87. Begue P, Kafetzis DA, Albin H, et al. Pharmacokinetics of roxithromycin in paediatrics. J Antimicrob Chemother 1987; 20 Suppl. B: 101-6
88. DiLorenzo C, Flores AF, Tomomasa T, et al. Effect of erythromycin on antroduodenal motility in children with chronic functional gastrointestinal symptoms. Dig Dis Sci 1994; 39: 1399-404
89. Ruiz NM, Ramirez-Ronda CH. Tetracyclines, macrolides, lincosamides and chloramphenicol. Bol Assoc Med PR 1990; 82: 8-17
90. Johnson RH. Community-acquired pneumonia: etiology, diagnosis, and treatment. Clin Ther 1988; 10: 568-73
91. Ellison MJ, Crabtree DW. Antibiotic therapy for common infections. Prim Care 1990; 17: 521-41
92. Nguyen MLT, Yu VL. Legionella infection. Clin Chest Med 1991; 12: 257-68
93. Vanderhoef JA, Young R, Kaufman SS, et al. Treatment of cyclic vomiting in childhood with erythromycin. J Pediatr Gastroenterol Nutr 1993; 17: 387-91
94. Atmar RL, Greenberg SB. Pneumonia caused by Mycoplasma pneumoniae and the TWAR agent. Semin Resp Infect 1989; 4: 19-31
95. Kernbaum S. Penicillins and macrolides in the treatment of community-acquired respiratory tract infections. Pediatr Infect Dis J 1987; 6: 328-31
96. Johnson DH, Cunha BA. Atypical pneumonias. Postgrad Med 1993; 93 (7): 69-72, 75, 76, 79, 80, 82
97. Edelstein PH, Meyer RD. Legionnaire's disease. Chest 1984; 85: 114-20
98. Edelstein PH. Legionnaires' disease. Clin Infect Dis 1993; 16: 741-9
99. Roig J, Carreres A, Domingo C. Treatment of Legionnaires' disease. Drugs 1993 Jul; 46 (1): 63-79
100. Korvick JA, Yu VL, Fang G-D. Legionella species as hospital-acquired respiratory pathogens. Semin Resp Infect 1987; 2: 34-47
101. Keys TF. Therapeutic considerations in the treatment of Legionella infections. Semin Resp Infect 1987; 2: 270-3
102. Fang G-D, Yu VL, Vickers RM. Infections caused by the Pittsburgh pneumonia agent. Semin Resp Infect 1987; 2: 262-6
103. Muder RR, Yu VL, Fang G-D. Community-acquired Legionnaires' disease. Semin Resp Infect 1989; 4: 32-9
104. Latare PA, Setness PA. Using erythromycin. Postgrad Med 1989; 86 (1): 55-9, 63
105. Centers for Disease Control and Prevention. 1993 sexually transmitted diseases treatment guidelines. Morb Mortal Wkly Rep 1993; 42 (RR-14): 1-102
106. Hool EW III. Treatment of syphilis: current recommendations, alternatives, and continuing problems. Rev Infect Dis 1989; 11 Suppl. 6: S1511-7
107. Martin DH. Chlamydial infections. Med Clin North Am 1990; 74: 1367-87
108. Majeroni BA. Chlamydial cervicitis: complications and new treatment options. Am Fam Phys 1994; 49: 1825-9
109. Oehme A, Musholt PB, Dreesbach K. Chlamydiae as pathogens - an overview of diagnostic techniques, clinical features, and therapy of human infections. Klin Wochenschr 1991; 69: 463-73
110. Rettig PJ. Chlamydial infections in pediatrics: diagnostic and therapeutic considerations. Pediatr Infect Dis J 1986; 5: 158-62
111. Graham JM, Blanco JD. Chlamydial infections. Prim Care 1990; 17: 85-9.
112. Toomey KE, Barnes RC. Treatment of Chlamydia trachomatis genital infection. Rev Infect Dis 1990; 12 Suppl. 6: S645-55
113. Lisby SM, Nahata MC. Recognition and treatment of chlamydial infections. Clin Pharm 1987; 6: 25-36
114. Bell TA. Chlamydia trachomatis. Mycoplasma hominis, and Ureaplasma urealyticum infections of infants. Semin Perinatol 1985; 9: 29-37
115. Thom DH, Grayston JT. Infections with Chlamydia pneumoniae strain TWAR. Clin Chest Med 1991; 12: 245-56
116. Grayston JT. Chlamydia pneumoniae strain TWAR pneumonia. Annu Rev Med 1992; 43: 317-23
117. Lisby-Sutch S, Nemec-Dwyer M, Deeter RG, et al. Therapy of otitis media. Clin Pharm 1990; 9: 15-34
118. Giebink GS, Canafax DM. Antimicrobial treatment of otitis media. Semin Resp Infect 1991; 6: 85-93
119. Waite KB, Crouse DT, Cassell GH. Therapeutic considerations for Ureaplasma urealyticum infections in neonates. Clin Infect Dis 1993; 17 Suppl. 1: S208-14
120. Klein MD. Streptococcal pharyngitis in children. Pediatr Emerg Care 1989; 5: 259-61
121. Loos GD. Pharyngitis, croup, and epiglottitis. Prim Care 1990; 17: 335-45
122. Kisel ca D. Group A beta-hemolytic streptococcal pharyngitis: current clinical concepts. Am Fam Phys 1994; 49: 1147-54
123. Huovinen P. Causes, diagnosis, and treatment of pharyngitis. Compr Ther 1990; 16(10): 59-65
124. Pilot MA, Qin XY. Macrolides and gastrointestinal motility. J Antimicrob Chemother 1988; 22 Suppl. B: 201-6
125. Mortazavi P, Mueller BA. Erythromycin in gastrointestinal motility disturbances. Ann Pharmacother 1992; 26: 1095-7
126. Longo WE, Vernava AM III. Prokinetic agents for lower gastrointestinal motility disorders. Dis Colon Rectum 1993; 36: 696-708
127. Catnach SM, Fairclough PD. Erythromycin and the gut. Gut 1992; 33: 397-401
128. Peeters TL. Erythromycin and other macrolides as prokinetic agents. Gastroenterology 1993; 105: 1886-99
129. Drenth JPH, Engels LGJB. Diabetic gastroparesis: a critical reappraisal of new treatment strategies. Drugs 1992 Oct; 44 (4): 537-53
130. Wold ER. Antimicrobial therapy of pediatric patients with sinusitis. J Allergy Clin Immunol 1992; 90: 469-73
131. Derrick CW, Reilly KM, Stallworth JR. Erythromycin in the treatment of streptococcal infections. Pediatr Infect Dis J 1985; 5: 172-6
132. Schlick W. The problems of treating atypical pneumonia. J Antimicrob Chemother 1993; 31 Suppl. C: 111-20
133. Ad Hoc Committee Report. Systemic antibiotics for treatment of acne vulgaris: efficacy and safety. Arch Dermatol 1975; 111 1630-6
134. Feldman WE. Pharyngitis in children. Postgrad Med 1993; 93 (3): 141, 142, 144, 145
135. Chen J-Y. Prophylaxis of ophthalmia neonatorum: comparison of silver nitrate, tetracycline, erythromycin and no prophylaxis. Pediatr Infect Dis J 1992; 11: 1026-30
136. Canadian Task Force on the Periodic Health Examination. Periodic health examination, 1992 update: 4. prophylaxis for gonococcal and chlamydial ophthalmia neonatorum. Can Med Assoc J 1992; 147: 1449-54
137. Holmberg Jr RE, Pavia T, Montgomery D, et al. Nosocomial Legionella pneumonia in the neonate. Pediatrics 1993; 92: 450-3
138. Tomomasa T, Miyazaki M, Koizumi T, et al. Erythromycin increases gastric antral motility in human premature infants. Biol Neonate 1993; 63: 349-52
139. Washington II JA, Wilson WR. Erythromycin: a microbial and clinical perspective after 30 years of clinical use (second of two parts). Mayo Clin Proc 1985; 60: 271-8
140. DuPont HL. Diarrhoeal disease: current concepts and future challenges. Trans R Soc Trop Med Hyg 1993; 87 Suppl. 3: 31-4
141. Meguro H, Arimasu O, Hiruma F, et al. Clinical evaluation of clarithromycin, a new macrolide antibiotic in children. Jpn J Antibiot 1989; 42: 255-62
142. Ogura H, Kubota H, Nomura I, et al. Clinical efficacy of clarithromycin in the field of pediatrics. Jpn J Antibiot 1989; 42: 401-10
143. Motohiro T, Sakata Y, Kuroiwa Y, et al. Clinical study on clarithromycin granule and tablet in the field of pediatrics. Jpn J Antibiot 1989; 42: 423-64
144. Tayama M, Ichioka T, Hosoda T, et al. Clinical experience with clarithromycin in the pediatric field. Jpn J Antibiot 1989; 42: 388-92
145. Tsutsui T, Haruta T, Kuroki S, et al. A clinical study on clarithromycin especially on its granular form for children, in pediatrics. Jpn J Antibiot 1989; 42: 381-7
146. Sekiguchi T, Okamoto T, Ohara K, et al. Clinical observations with clarithromycin in pediatrics. Jpn J Antibiot 1989; 42: 411-9
147. Furukawa S, Okada T. A clinical evaluation of clarithromycin in the treatment of pediatric infections. Jpn J Antibiot 1989; 42: 420-2
148. Hattori K, Higashino H, Takebe A, et al. Clinical study of clarithromycin, a new macrolide antibiotic, in children. Jpn J Antibiot 1989; 42: 371-80
149. Casellas JM, Rodriguez HA, Fernandez-MacLoughlin GJ, et al. Efficacy of roxithromycin in the treatment of acute otitis media in infants. Br J Clin Prac 1988; Suppl. 55: 113-4
150. Bazet MC, Blanc F, Churndermpadetsuk S, et al. Roxithromycin in the treatment of paediatric infections. Br J Clin Prac 1988; Suppl. 55: 117-8
151. Stamboulian D, Fernandez-MacLoughlin GJ, Lanoel JL, et al. Clinical evaluation of roxithromycin in 101 children. Br J Clin Prac 1988; Suppl. 55: 115-6
152. Kafetzis DA, Blanc F. Efficacy and safety of roxithromycin in treating paediatric patients: a European multicentre study. J Antimicrob Chemother 1987; 20 Suppl. B: 171-7
153. Rodriguez-Solares A, Perez-Gutierrez F, Prosperi J, et al. A comparative study of the efficacy, safety and tolerance of azithromycin, dicloxacillin and flucloxacillin in the treatment of children with acute skin and skin-structure infections. J Antimicrob Chemother 1993; 31 Suppl. E: 103-9
154. Weippl G. Multicentre comparison of azithromycin versus erythromycin in the treatment of paediatric pharyngitis or tonsillitis caused by group A streptococci. J Antimicrob Chemother 1993; 31 Suppl. E: 95-101
155. Hamill J. Multicentre evaluation of azithromycin and penicillin V in the treatment of acute streptococcal pharyngitis and tonsillitis in children. J Antimicrob Chemother 1993; 31 Suppl. E: 89-94
156. Schaad UB. Multicentre evaluation of azithromycin in comparison with co-amoxiclav for the treatment of acute otitis media in children. J Antimicrob Chemother 1993; 31 Suppl. E: 81-8
157. Mohs E, Rodriguez-Solares A, Rivas E, et al. A comparative study of azithromycin and amoxycillin in paediatric patients with otitis media. J Antimicrob Chemother 1993; 31 Suppl. E: 73-9
158. Daniel RR. Comparison of azithromycin and co-amoxiclav in the treatment of otitis media in children. J Antimicrob Chemother 1993; 31 Suppl. E: 65-71
159. Pestalozza G, Cioce C, Facchini M. Azithromycin in upper respiratory tract infections: a clinical trial in children with otitis media. Scand J Infect Dis 1992; Suppl. 83: 22-5
160. Hammerschlag MR, Golden NH, Oh K, et al. Single dose of azithromycin for the treatment of genital chlamydial infections in adolescents. J Pediatr 1993; 122: 961-5
161. Still JG, Hubbard WC, Poole JM, et al. Comparison of clarithromycin and penicillin VK suspensions in the treatment of children with streptococcal pharyngitis and review of currently available therapies. Pediatr Infect Dis J 1993; 12: S134-41
162. Hebert AA, Still JG, Reuman PD. Comparative safety and efficacy of clarithromycin and cefadroxil suspensions in the treatment of mild to moderate skin and skin structure infections in children. Pediatr Infect Dis J 1993; 12: S112-7
163. McCarty JM, Phillips A, Wiisanen R. Comparative safety and efficacy of clarithromycin and amoxicillin/clavulanate in the treatment of acute otitis media in children. Pediatr Infect Dis J 1993; 12: S122-7
164. Pukander JS, Jero JP, Kaprio EA, et al. Clarithromycin vs amoxicillin suspensions in the treatment of pediatric patients with acute otitis media. Pediatr Infect Dis J 1993; 12: S118-21
165. Gooch WM III, Gan VN, Corder WT, et al. Clarithromycin and cefaclor suspensions in the treatment of acute otitis media in children. Pediatr Infect Dis J 1993; 12: S128-33
166. Coles SJ, Addlestone MB, Kamdar MK, et al. A comparative study of clarithromycin and amoxycillin suspensions in the treatment of pediatric patients with acute otitis media. Infection 1993;21:272-8
167. Eichenwald HF. Adverse reactions to erythromycin. Pediatr Infect Dis J 1986; 5: 147-50
168. Periti P, Mazzei T, Mini E, et al. Adverse effects of macrolide antibacterials. Drug Saf 1993; 9: 346-64
169. Pessayre D, Larrey D, Funck-Brentano C, et al. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother 1985; 16 Suppl. A: 181-94
170. Brummett RE, Fox KE. Vancomycin- and erythromycin-induced hearing loss in humans. Antimicrob Agents Chemother 1989; 33: 791-6
171. Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents. Ann Intern Med 1984; 101: 92-104
172. Brummett RE. Ototoxic liability of erythromycin and analogues. Otolaryngol Clin North Am 1992; 26: 811-9
173. Benoit A, Bobiou C, Villain E, et al. QT long et arrêt circulatoire après une injection d'érythromycine chez un nouveau-né. Arch Fr Pediatr 1991; 48: 39-41
174. Farrar HC, Walsh-Sukys MC, Kyllonen K, et al. Cardiac toxicity associated with intravenous erythromycin lactobionate: two case reports and a review of the literature. Pediatr Infect Dis J 1993; 12: 688-91
175. Begue P, Astruc J, Safran C, et al. The overall safety of oral roxithromycin in pediatric clinical studies [abstract no. 124]. 2nd International Conference on the Macrolides, Azalides, and Streptogramins; 1994, Jan 19-22: Venice. Atlanta (GA): Wallace Communications, 1994
176. Hopkins S. Clinical safety and tolerance of azithromycin in children. J Antimicrob Chemother 1993; 31 Suppl. E: 111-7
177. Tseng A, Dolovich L, Salit I. Azithromycin ototoxicity in HIV patients [abstract no. LM19]. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy; 1995, Sep 17-20: San Francisco (CA). Washington (DC): American Society for Microbiology, 1995
178. Craft JC, Siepman N. Overview of the safety profile of clarithromycin suspension in pediatric patients. Pediatr Infect Dis J 1993; 12: S142-7
179. Guay DRP, Patterson DR, Seipman N, et al. Overview of the tolerability profile of clarithromycin in preclinical and clinical trials. Drug Saf 1993; 8: 350-64
180. Ludden TM. Pharmacokinetic interactions of the macrolide antibiotics. Clin Pharmacokinet 1985; 10: 63-79
181. Descotes J, Andre P, Evreux JC. Pharmacokinetic drug interactions with macrolide antibiotics. J Antimicrob Chemother 1985; 15: 659-64
182. Rodin SM, Johnson BF. Pharmacokinetic drug interactions with digoxin. Clin Pharmacokinet 1988; 15: 227-44
183. Periti P, Mazzei T, Mini E, et al. Pharmacokinetic drug interactions of macrolides. Clin Pharmacokinet 1992; 23: 106-31
184. Orme ML'E, Back DJ. Interactions between oral contraceptive steroids and broad-spectrum antibiotics. Clin Exp Dermatol 1986; 11: 327-31
185. Jonkman JHG, Upton RA. Pharmacokinetic drug interactions with theophylline. Clin Pharmacokinet 1984; 9: 309-34
186. Rieder MJ, Spino M. The theophylline-erythromycin interaction. J Asthma 1988; 25: 195-204
187. Upton RA. Pharmacokinetic interactions between theophylline and other medications. Clin Pharmacokinet 1991; 20: 66-80
188. Jonkman JHG. Therapeutic consequences of drug interactions with theophylline pharmacokinetics. J Allergy Clin Immunol 1986; 78: 736-42
189. Kutt H. Interactions between anticonvulsants and other commonly prescribed drugs. Epilepsia 1984; 25 Suppl. 2: S118-31
190. Baciewicz AM. Carbamazepine drug interactions. Ther Drug Monitor 1986; 8: 305-17
191. Wadhwa NK, Schroeder TJ, Pesce AJ, et al. Cyclosporine drug interactions: a review. Ther Drug Monitor 1987; 9: 399-406
192. Sands M, Brown RB. Interactions of cyclosporin with antimicrobial agents. Rev Infect Dis 1989; 11: 691-7
193. Baciewicz AM, Baciewicz FA. Cyclosporine pharmacokinetic drug interactions. Am J Surg 1989; 157: 264-71
194. Yee GC, McGuire TR. Pharmacokinetic drug interactions with cyclosporin. Clin Pharmacokinet 1990; 19: 319-22
195. Mattila MJ, Idanpaan-Heikkila JJ, Tornwall M, et al. Oral single doses of erythromycin and roxithromycin may increase the effects of midazolam on human performance. Pharmacol Toxicol 1993; 73: 180-5
196. Honig PK, Woosley RL, Zamani K, et al. Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther 1992; 52: 231-8
197. Honig P, Wortham D, Zamani K, et al. Effect of erythromycin, clarithromycin, and azithromycin on the pharmacokinetics of terfenadine [abstract]. Clin Pharmacol Ther 1993; 53: 161
198. Hashiguchi K, Niki Y, Soejima R. Roxithromycin does not raise serum theophylline levels [letter]. Chest 1992; 102: 653-4
199. Meyer B, Muller F, Wessels P, et al. A model to detect interactions between roxithromycin and oral contraception. Clin Pharmacol Ther 1990; 47: 671-4
200. Billand EM, Guillemain R, Fortineau N, et al. Interaction between roxithromycin and cyclosporin in heart transplant patients. Clin Pharmacokinet 1990; 19: 499-502
201. Paulsen O, Nilsson L-G, Saint-Salvi B, et al. No effect of roxithromycin on pharmacokinetic or pharmacodynamic properties of warfarin and its enantiomers. Pharmacol Toxicol 1988; 63: 215-20
202. 2-blockers and antacids on gastrointestinal absorption. Eur J Clin Microbiol Infect Dis 1942; 11: 465-8
203. Vance E, Watson-Bitar M, Gustavson L, et al. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob Agents Chemother 1995; 39: 1355-60
204. Welling PG. Interactions affecting drug absorption. Clin Pharmacokinet 1984; 9: 404-34
205. ®) Product Monograph. Abbott Park (IL): Abbott Laboratories, 1994 Jul